Additionally, Jikuya et al. (2022) discovered high expression of the mesenchymal to epithelial transition factor (MET) in various histological types of BHDS‐associated renal tumors, suggesting that MET inhibitors such as cabozantinib and crizotinib may provide promising therapeutic options for treating BHDS‐associated renal tumors. Here, MET is linked to kidney neoplasm.